CHIMERIC THERAPEUTICS

Annual General Meeting

Jennifer Chow
CEO and Managing Director
November 15, 2022

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

CHIMERICTHERAPEUTICS

COMMITTED TO BRINGING THE PROMISE OF CELL THERAPY TO LIFE

Traditional drug development focuses on delaying disease progression - not on a cure.

We believe that novel cellular therapies have the promise to cure cancer.

To bring that promise to life for more patients, the mission of Chimeric is to discover, develop and commercialize the most promising and innovative cell therapies.

"We can now conclude that CAR-T cells can CURE patients with leukemia"

Dr Carl June, MD
Richard W. Vague Professor in Immunotherapy
Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine

CELL THERAPY

ANTICIPATED TO BE THE FASTEST GROWING MARKET IN ONCOLOGY

2022 MARKET	
$265 BN	ONCOLOGY
$10.69 BN	CELL THERAPY

2027 MARKET	
$581BN	ONCOLOGY
$42.37BN	CELL THERAPY

CAGR	
8.2%	ONCOLOGY
31.7%	CELL THERAPY

Market Data Forecast, Global Cell Therapy Market Size, Share, Trends, Growth & COVID-19 Impact Analysis Report – Segmented By Technology, Type, Cell Source, Application, End-Users and Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) – Industry Forecast (2022 to 2027)

CHIMERIC THERAPEUTICS
CORPORATE SNAPSHOT

- Multiple Assets with Positive Phase 1 Signals
- Robust Clinical Development Plans with Broad Therapeutic Focus
- Innovative and Diversified Portfolio of Next Generation Technologies
- Industry Leading Team with Extensive Cell Therapy Experience

ASX: CHM



Share Price Nov. 13:
52 Week Range: 0.08-0.31
Shares on Issue: 425 M

Market Cap Nov. 13: ~$36M
Net Cash: AUS $8M (Sept 22)
Board / Mgmt. Ownership: 20%

A YEAR OF MAJOR MILESTONES:

November 2021- November 2022

CORE NK Option
(CHM 0201)
From Case Western Reserve University
November **2021**

Positive DL1 Data
November **2021**
Phase 1A CLTX CAR T
(CHM 1101)
Clinical Trial

CDH17 CAR T
(CHM 2101)
Sponsored Research Agreement with Penn
February **2022**

Positive DL2 Data
February **2022**
Phase 1A CLTX CAR T
(CHM 1101)
Clinical Trial

CORE NK
(CHM 0201)
Exercise of Option
May **2022**

CDH17 Nature Cancer
March **2022**
Preclinical
Publication

CDH17 VECTOR
(CHM 2101)
Licensed from University of Pennsylvania
June **2022**

Positive Phase 1 Data
March **2022**
CORE NK
(CHM 0201)
Clinical Trial

CORE NK
(CHM 0201)
Sponsored Research Agreement
November **2022**

CORE NK Combination Trial
June **2022**
Clearance from FDA
(CHM 0201+)

CHIMERIC CELL THERAPY PORTFOLIO

CUTTING EDGE INNOVATION WITH BROAD COMMERCIAL OPPORTUNITY

Novel Design

T Cells

Autologous

(personal)

- **CLTX CAR T** (ICT/ ICV) — GBM, Phase 1
- **CLTX CAR T** (IV) — Solid Tumor
- **CDH17 CAR T** — Solid Tumor

City of Hope

Penn

NK Cells

Allogeneic

(off-the-shelf)

CORE-NK Platform
Phase 1 Complete

- **Next Gen. CORE-NK Platform**
- **CLTX CAR-NK**
- **CDH17 CAR-NK**
- **Undisclosed** CAR-NK

Case Western Reserve University Est. 1826

DIFFERENTIATING CHIMERIC

A DIVERSIFIED PORTFOLIO WITH A FOCUS ON CURATIVE INTENT



CHIMERIC MANAGEMENT TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

EXPERIENCE

75+ Years of Cell Therapy Experience

EXPERTISE

50+ Development Programs

PROVEN

4/6 Of the FDA-Approved CAR T Cell Therapies



CHM 0201, 0301, 1301, 2301, 3301

Natural Killer Cell Therapies



OFF THE SHELF (ALLOGENEIC) NK THERAPY DEVELOPMENT

ON DEMAND THERAPY



Leukapheresis (blood draw) from a healthy donor

Isolation of the Natural Killer Cells

Engineering of the Natural Killer Cells

1000's of Doses Manufactured at Once

Off the Shelf Availability for Patients on Demand

Healthier starting material	Scalable manufacturing with reduced costs	Rapidly available, off the shelf	Ability to reach more patients

CHM 0201 PHASE 1 STUDY RESULTS

PROMISING RESULTS ACROSS ALL KEY ENDPOINTS

SAFETY	PERSISTENCE	EXPANSION	EFFICACY IN SOLID TUMOURS	EFFICACY IN BLOOD CANCERS
ESTABLISHED SAFETY across 3 Dose Levels NO GVHD WITH UNIVERSAL DONOR CELLS	28 DAY PERSISTENCE OF CORE NK CELLS DEMONSTRATED	LARGE SCALE MANUFACTURING SUCCESS FROM A SINGLE DONOR	33% DISEASE CONTROL RATE IN SOLID TUMOURS 66% DURABILITY OF RESPONSE PAST DAY 100	100% DISEASE CONTROL RATE IN BLOOD CANCERS 15+ MONTH COMPLETE RESPONSE

Transplantation and Cellular Therapy, 2022, ISSN 2666-6367

CORE NK (CHM 0201) PHASE 1 STUDY RESULTS

ONGOING COMPLETE RESPONSE

PATIENT #8
33-year-old female

DIAGNOSIS: AML with therapy related High-Risk MDS with circulating blasts and high tumour burden

HISTORY: Progressive disease with prior allogeneic transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD



Transplantation and Cellular Therapy, 2022, ISSN 2666-6367

ENHANCING THE CHM 0201 EFFICACY SIGNAL

NEW PHASE 1B CHM 0201 CLINICAL TRIAL

To identify a combination therapy that could enhance the initial efficacy signal seen with CHM 0201 (CORE NK) cells by modulating the tumour microenvironment

CHM 0201 + VACTOSERTIB



CORE (Clinically validated, off the shelf, robust and enhanced) NK cells



A clinical drug candidate that inhibits TGF- **β** signaling, modulating the tumour microenvironment

FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH VACTOSERTIB

A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib

Study Initiation: Sept. 9, 2022
Enrollment: 12 Patients
Estimated Completion: Dec. 2023

Eligible Patients:
Relapse or refractory solid tumours and hematological malignancies

Clinical Trials.gov Identifier:
NCT05400122

CHM 1101

CLTX CAR T Cell Therapy



PERSONALIZED (AUTOLOGOUS) T CELL THERAPY DEVELOPMENT

HARNESSING AN INDIVIDUAL'S OWN IMMUNE SYSTEM



Leukapheresis (blood draw) from an individual patient

Isolation of the T Cells



Engineering of the T Cells with Chimeric Antigen Receptors (CARs)

Individual patients engineered CAR T Cells are frozen for transport



Personalized therapy for the individual patient

Starting cells come from individual patient	Unlikely that a patient's own immune system will attack the cells	No need for anti-rejection medications	Proven to be curative in blood cancers

CHM 1101 (CLTX CAR T)

Encouraging Initial Data in Glioblastoma

Early Signs of Efficacy with Local Administration

- 70% Disease Control Rate
- Up to 14 weeks of durability
- Regional tumour control where CLTX CAR T was administered



No recurrence of CHM 1101 treated tumour

Rapid tumour progression where CHM 1101 was not administered

"This preliminary data is encouraging as it demonstrates safety with dual routes of administration. We now look forward to advancing the trial to higher dose levels which may provide more therapeutic benefit to patients"

Behnam Badie, M.D., Professor and Chief, Division of Neurosurgery; Director, Brain Tumor Program, Department of Surgery, City of Hope.

SNO 2021, Abstract CTIM-29, "Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma"

CHM 2101

CDH17 CAR T Cell Therapy



CHM 2101: (CDH17 CAR T)

A NOVEL 3rd GENERATION CAR T DESIGNED FOR SOLID TUMORS AND HEADED TO THE CLINIC

Preclinical data featured in Nature Cancer





Dr. Xianxin Hua, M.D., Ph.D.

Dr. Carl June M.D.

Efficacy

Complete eradication of tumor cells with no relapse



Safety

High tumor-specific activity *in vivo* with no on-target / off-tumor toxicity



Feng et al. Nature Cancer, 2022. https://doi.org/10.1038/s43018-022-00344-7

AUSTRALIA'S MOST ROBUST AND ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE

JAN. 2021

1
ASSET IN DEVELOPMENT

1
ONGOING CLINICAL TRIAL

0
TRIALS WITH EARLY POSITIVE CLINICAL SIGNALS

1
DISEASE AREA IN DEVELOPMENT

NOV. 2022

7
ASSETS IN DEVELOPMENT

3
ONGOING CLINICAL TRIALS

2
TRIALS WITH EARLY POSITIVE CLINICAL SIGNALS

10
DISEASE AREAS IN DEVELOPMENT

KEY MILESTONES

CHIMERIC THERAPEUTICS

NEXT 6-12 MONTHS

	CHM 2101	FDA IND Clearance
	CHM 2101	Manufacture & Release of CDH17 Vector
	CHM 1101	Completion of GBM Phase 1 Dose Escalation
	CHM 1101	Second CHM GBM Trial Site Initiation
	CHM 1101	First Patient Dosed CHM GBM Trial
	CHM 1101	Initiation of CHM Ph. 1A/B GBM Trial
	CHM 0201	First Patient Dosed in CORE NK Combo Trial
	CHM 1101	Completion of COH Dose Level 3
✓	CHM 0301	Execute SRA with CWRU
	CHM 0201	Execute CORE NK Licensing Agreement
✓	CHM 0201	FDA Clearance for CORE NK Combo Trial
✓	CHM 2101	Execute Agreement for CDH17 Vector License
✓	CHM 2101	Technology Transfer of CDH17 to WuXi
✓	CHM 1101	Manufacture & Release of CLTX Vector
✓	CHM 1101	Strategic Partnerships to Support GBM Trial

CHIMERIC THERAPEUTICS

Australian Leadership in Cell Therapy

Opportunity

7 novel assets in the fast-growing segment in oncology drug development

Clinical Promise

Initial positive signals from 2 phase 1 clinical trials

Near Term Value

Multiple key clinical milestones over the next 12 – 24 months creating value

Proven Expertise

World class team with success driving development to commercial approval

CONTACT INFORMATION

Jennifer Chow
Chief Executive Officer
Chimeric Therapeutics Ltd
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul A. Hopper
Executive Chairman
Chimeric Therapeutics Ltd
Cell: +61 406671515
paulhopper@lifescienceportfolio.com

CHIMERIC THERAPEUTICS